Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Products under Development by Stage of Development | 7 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Products under Development by Therapy Area | 8 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Products under Development by Indication | 9 | 2 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Products under Development by Companies | 13 | 2 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Therapeutics Assessment | 15 | 4 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 1 |
| Assessment by Molecule Type | 18 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Companies Involved in Therapeutics Development | 19 | 5 |
| Advenchen Laboratories, LLC | 19 | 1 |
| Astellas Pharma Inc. | 20 | 1 |
| Bristol-Myers Squibb Company | 21 | 1 |
| Lead Discovery Center GmbH | 22 | 1 |
| Pfizer Inc. | 23 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Drug Profiles | 24 | 13 |
| AL-2846 Drug Profile | 24 | 1 |
| BMS-777607 Drug Profile | 25 | 2 |
| crizotinib Drug Profile | 27 | 7 |
| OSI-296 Drug Profile | 34 | 1 |
| Small Molecules to Antagonize MST1R for Oncology Drug Profile | 35 | 1 |
| Small Molecules to Antagonize RON Kinase for Oncology Drug Profile | 36 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Dormant Projects | 37 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Discontinued Products | 38 | 1 |
| Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) Featured News &Press Releases | 39 | 12 |
| Jun 14, 2016: AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer | 39 | 1 |
| Jun 03, 2016: Crizotinib Demonstrates Clinical Benefit in Phase II Study of East Asian Patients with ROS1-Positive Non-Small Cell Lung Cancer | 39 | 1 |
| Mar 11, 2016: XALKORI (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer | 40 | 1 |
| Dec 08, 2015: Pfizer Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for XALKORI (crizotinib) for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer | 41 | 1 |
| Nov 25, 2015: Pfizer Receives European Approval to Expand Use of XALKORI (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer | 42 | 1 |
| Nov 18, 2015: Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer | 42 | 1 |
| Sep 08, 2015: Study defines criteria for MET-driven lung cancer suitable for crizotinib treatment | 43 | 1 |
| Apr 21, 2015: Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer | 44 | 1 |
| Mar 16, 2015: ASLAN announces positive phase 1 results with ASLAN002 | 45 | 1 |
| Dec 03, 2014: Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer s XALKORI (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Ca... | 45 | 1 |
| Dec 02, 2014: Biologics selected as limited distribution partner for Xalkori (crizotinib) | 46 | 1 |
| Sep 27, 2014: Crizotinib treatment effective against ROS1-positive lung cancer | 47 | 1 |
| Aug 26, 2014: Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen | 48 | 1 |
| Mar 25, 2014: Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer | 49 | 1 |
| Nov 20, 2013: Pfizer Receives FDA Approval for crizotinib to Treat Metastatic Non-Small Cell Lung Cancer | 49 | 2 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |